ARCHIVES

Interim Analysis of Phase III Data Preferable For Accelerated Approval, FDA’s Pazdur Says

This article is from The Cancer Letter archive.

Vol. 28 No. 32 | September 6, 2002

Download PDF Visit The Full Archive

Related Articles

McDonald’s Charity Commits $5 Million To Pediatric Research

May 17, 1991

NCI Program: Hughes Institute Official To Head Cancer Biology

July 23, 1999

Peter Boyle Elected IARC Director

May 23, 2003

R01 Payline To Increase From 21st to 22nd Percentile; Barcelona Hospital Wins BMS Cancer Research Grant

June 14, 2002

Interview with Claudia Henschke: Observational Study Of Spiral CT Should Change Medical Practice, She Says.

November 3, 2006

Sorafenib Targets AML Driven By Mutant FLT3 Gene

February 29, 2008